Range Financial Group LLC Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Range Financial Group LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 29,855 shares of the biotechnology company's stock, valued at approximately $994,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Diversified Trust Co boosted its position in shares of Exelixis by 4.7% during the fourth quarter. Diversified Trust Co now owns 20,136 shares of the biotechnology company's stock valued at $671,000 after buying an additional 902 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Exelixis by 22.4% during the 4th quarter. CWA Asset Management Group LLC now owns 27,201 shares of the biotechnology company's stock valued at $906,000 after acquiring an additional 4,979 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Exelixis by 5.1% during the 4th quarter. Nordea Investment Management AB now owns 233,348 shares of the biotechnology company's stock valued at $7,878,000 after acquiring an additional 11,331 shares during the last quarter. Everence Capital Management Inc. bought a new stake in shares of Exelixis in the fourth quarter worth approximately $271,000. Finally, GAMMA Investing LLC raised its holdings in shares of Exelixis by 37.2% during the fourth quarter. GAMMA Investing LLC now owns 4,129 shares of the biotechnology company's stock valued at $137,000 after purchasing an additional 1,119 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director George Poste sold 30,000 shares of Exelixis stock in a transaction on Friday, November 1st. The shares were sold at an average price of $34.00, for a total value of $1,020,000.00. Following the completion of the transaction, the director now directly owns 169,020 shares of the company's stock, valued at $5,746,680. This trade represents a 15.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now owns 486,059 shares in the company, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 314,736 shares of company stock worth $10,849,110 in the last quarter. 2.85% of the stock is owned by corporate insiders.

Exelixis Price Performance

Shares of NASDAQ EXEL traded up $1.01 during mid-day trading on Tuesday, reaching $34.21. The company's stock had a trading volume of 2,441,371 shares, compared to its average volume of 1,907,988. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.97. The stock has a fifty day moving average of $34.78 and a two-hundred day moving average of $28.63. The firm has a market capitalization of $9.77 billion, a PE ratio of 21.93, a P/E/G ratio of 0.89 and a beta of 0.53.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the prior year, the company posted $0.10 EPS. The firm's revenue for the quarter was up 14.3% compared to the same quarter last year. Analysts anticipate that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. UBS Group initiated coverage on Exelixis in a report on Thursday, September 19th. They issued a "neutral" rating and a $30.00 price objective for the company. Guggenheim increased their target price on Exelixis from $33.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday. The Goldman Sachs Group raised Exelixis to a "strong sell" rating in a research report on Tuesday, October 15th. Finally, BMO Capital Markets cut shares of Exelixis from an "outperform" rating to a "market perform" rating and increased their price objective for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.00.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.